PDL BioPharma, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2007-10: Study NCT00548717; Company role Collaborator; Phase Phase 2; Status Terminated.
- 2006-09: Study NCT00355901; Company role Lead sponsor; Phase Observational; Status Terminated.
- 2006-08: Study NCT00279435; Company role Collaborator; Phase Phase 2, Phase 3; Status Terminated.
- 2006-02: Study NCT00279422; Company role Collaborator; Phase Phase 2, Phase 3; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2007-10 | NCT00548717 Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation | Collaborator Lead: Dana-Farber Cancer Institute | Phase 2 | Terminated Results posted | Graft-vs-Host Disease | 15 | 2013-09 |
| 2006-09 | NCT00355901 An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis | Lead sponsor | Observational | Terminated | Ulcerative Colitis | 300 | 2012-11 |
| 2006-08 | NCT00279435 Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study | Collaborator Lead: Facet Biotech | Phase 2, Phase 3 | Terminated | Ulcerative Colitis | 25 | 2007-08 |
| 2006-02 | NCT00279422 A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis | Collaborator Lead: Facet Biotech | Phase 2, Phase 3 | Terminated | Ulcerative Colitis | 127 | 2007-08 |
| 2005-12 | NCT00281294 A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis | Lead sponsor | Phase 2 | Terminated | Arthritis, Rheumatoid | 40 | 2006-12 |
| 2005-04 | NCT00109161 Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis | Lead sponsor | Phase 2 | Completed | Multiple Sclerosis | 270 | 2006-10 |
| 2005-02 | NCT00267722 Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease | Collaborator Lead: Facet Biotech | Phase 2 | Completed | Crohn's Disease | 18 | 2006-12 |
| 2005-02 | NCT00267709 Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease | Collaborator Lead: Facet Biotech | Phase 2 | Completed | Crohn's Disease | 18 | 2006-12 |
| 2004-12 | NCT00099970 Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy | Lead sponsor | Phase 2 | Completed | Melanoma; Metastases | 40 | 2006-03 |
| 2004-01 | NCT00325793 IV Double and Triple Concentrated Nicardipine for Stroke and ICH | Collaborator Lead: OSF Healthcare System | Phase 4 | Unknown | Hypertension | 50 | |
| 2004-01 | NCT00267306 Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis | Collaborator Lead: Facet Biotech | Phase 1, Phase 2 | Completed | Severe Ulcerative Colitis | 144 | 2006-12 |
| 2000-10 | NCT00014664 Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Lead sponsor | Phase 2 | Unknown | Lymphoma | ||
| NCT00502294 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis | Collaborator Lead: Facet Biotech | Phase 3 | Withdrawn | Intravenous Steroid-Refractory Ulcerative Colitis | 150 |